Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

IgA nephropathy

J H Galla1

  • 1University of Cincinnati Medical Center, Ohio 45267-0585, USA.

Kidney International
|February 1, 1995
PubMed
Summary
This summary is machine-generated.

Immunoglobulin A nephropathy (IgAN) is a common kidney disease, primarily diagnosed via kidney biopsy. While treatments are limited, future therapies and kidney transplants offer hope for patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular genetics in IgA nephropathy.

Nephron·2001
Same author

Pathways for HCO3-reabsorption in mouse medullary collecting duct segments.

The Journal of laboratory and clinical medicine·2000
Same author

Economics of an academic renal division: an approach.

Seminars in nephrology·2000
Same author

NH4+ secretion in inner medullary collecting duct in potassium deprivation: role of colonic H+-K+-ATPase.

Kidney international·1999
Same author

HCO-3 reabsorption in renal collecting duct of NHE-3-deficient mouse: a compensatory response.

The American journal of physiology·1999
Same author

Rewarding teaching faculty with a reimbursement plan.

Journal of general internal medicine·1999
Same journal

KDIGO Life Cycle of Guideline Development Series Part 6: Bridging the Gap between Guidelines and Clinical Practice: The KDIGO Approach to Global Implementation and Education in Nephrology.

Kidney international·2026
Same journal

KDIGO Life Cycle of Guideline Development Series Part 5: Guideline updates and a living model for the future.

Kidney international·2026
Same journal

Crystal-storing histiocytosis causing severe acute kidney injury.

Kidney international·2026
Same journal

Peritoneal dialysis in a patient with extensive burn scarring.

Kidney international·2026
Same journal

COPA syndrome unmasked by anti-neutrophil cytoplasmic antibody-positive immune-complex nephritis.

Kidney international·2026
Same journal

Monitoring anti-nephrin antibodies in the management of recurrent diffuse podocytopathy.

Kidney international·2026
See all related articles

Area of Science:

  • Nephrology
  • Immunology
  • Pathology

Background:

  • Immunoglobulin A nephropathy (IgAN) is the most prevalent form of glomerulonephritis globally.
  • It disproportionately affects men and is less common in Black populations.
  • Clinical presentations vary, including macroscopic hematuria, microscopic hematuria with proteinuria, nephrotic syndrome, or acute renal failure.

Purpose of the Study:

  • To summarize the current understanding of IgAN, including its epidemiology, diagnosis, pathogenesis, clinical course, and therapeutic options.
  • To highlight the diagnostic challenges and the need for reliable non-invasive biomarkers.
  • To discuss the potential of emerging therapies and the efficacy of kidney transplantation.

Main Methods:

  • Diagnosis relies on immunohistologic examination of kidney biopsies, specifically identifying mesangial deposition of IgA.

Related Experiment Videos

  • Currently, no blood or urine tests are sufficiently reliable for definitive diagnosis.
  • Pathogenesis research suggests roles for polyclonal immunoglobulin stimulation and IgA structural abnormalities.

    • Main Results:

    • Approximately 30% of IgAN patients progress to end-stage renal disease (ESRD) within 20 years, especially those with hypertension, heavy proteinuria, or renal insufficiency.
    • Autoantibodies are frequently detected in patients with IgAN and Henoch-Schönlein purpura (HSP).
    • Kidney transplantation demonstrates excellent allograft survival rates.

    Conclusions:

    • IgAN diagnosis remains dependent on kidney biopsy, with ongoing research into its unknown pathogenesis.
    • Current therapeutic strategies are limited, but future treatments targeting mesangial proliferation and sclerosis pathways show promise.
    • Kidney transplantation is a viable and successful option for end-stage IgAN.